ProVise Management Group’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$909K Buy
12,661
+7
+0.1% +$539 0.07% 143
2025
Q4
$1M Sell
12,654
-37
-0.3% -$2.92K 0.07% 134
2025
Q3
$957K Sell
12,691
-9
-0.1% -$617 0.07% 134
2025
Q2
$876K Sell
12,700
-150
-1% -$9.84K 0.07% 136
2025
Q1
$871K Sell
12,850
-4,824
-27% -$289K 0.07% 136
2024
Q4
$793K Sell
17,674
-60,997
-78% -$3.42M 0.07% 142
2024
Q3
$4.95M Sell
78,671
-83,387
-51% -$4.86M 0.39% 69
2024
Q2
$9.57M Buy
162,058
+8,875
+6% +$555K 0.81% 34
2024
Q1
$12.2M Buy
153,183
+12,844
+9% +$981K 1.06% 29
2023
Q4
$11.1M Buy
140,339
+4,964
+4% +$353K 0.94% 30
2023
Q3
$9.45M Buy
135,375
+6,154
+5% +$436K 0.88% 33
2023
Q2
$8.93M Sell
129,221
-699
-0.5% -$49.7K 0.81% 36
2023
Q1
$9.65M Sell
129,920
-22,497
-15% -$1.89M 0.92% 31
2022
Q4
$14.2M Buy
152,417
+4,104
+3% +$396K 1.44% 16
2022
Q3
$14.1M Sell
148,313
-639
-0.4% -$63.3K 1.58% 12
2022
Q2
$13.8M Buy
148,952
+783
+0.5% +$76.4K 1.47% 14
2022
Q1
$15M Buy
148,169
+2,711
+2% +$285K 1.42% 12
2021
Q4
$15M Buy
145,458
+447
+0.3% +$41.3K 1.36% 12
2021
Q3
$12.3M Buy
145,011
+515
+0.4% +$43.1K 1.22% 14
2021
Q2
$12.1M Sell
144,496
-970
-0.7% -$79.4K 1.23% 14
2021
Q1
$10.9M Buy
145,466
+4,125
+3% +$300K 1.18% 14
2020
Q4
$9.65M Buy
141,341
+3,685
+3% +$240K 1.11% 17
2020
Q3
$8.04M Buy
137,656
+2,755
+2% +$171K 1.08% 21
2020
Q2
$8.77M Buy
134,901
+1,570
+1% +$98.9K 1.26% 15
2020
Q1
$7.91M Sell
133,331
-2,388
-2% -$159K 1.33% 13
2019
Q4
$10.1M Buy
135,719
+1,012
+0.8% +$71.1K 1.24% 17
2019
Q3
$8.5M Buy
134,707
+10,490
+8% +$622K 1.13% 20
2019
Q2
$6.77M Buy
124,217
+28,490
+30% +$1.53M 0.91% 33
2019
Q1
$5.16M Buy
95,727
+11,422
+14% +$705K 0.72% 40
2018
Q4
$5.52M Buy
84,305
+51,745
+159% +$3.86M 0.87% 34
2018
Q3
$2.56M Sell
32,560
-252
-0.8% -$18K 0.34% 89
2018
Q2
$2.11K Buy
32,812
+1,994
+6% +$131K 0.16% 120
2018
Q1
$1.92M Buy
30,818
+5,297
+21% +$380K 0.28% 101
2017
Q4
$1.85M Buy
25,521
+821
+3% +$59.7K 0.27% 100
2017
Q3
$2.01M Sell
24,700
-226
-0.9% -$17.9K 0.29% 97
2017
Q2
$2M Sell
24,926
-675
-3% -$53.3K 0.3% 97
2017
Q1
$2.01M Sell
25,601
-300
-1% -$23.9K 0.32% 93
2016
Q4
$2.04M Sell
25,901
-1,873
-7% -$152K 0.35% 92
2016
Q3
$2.47M Buy
27,774
+366
+1% +$34.5K 0.43% 72
2016
Q2
$2.63M Sell
27,408
-2,666
-9% -$266K 0.48% 64
2016
Q1
$3.12M Buy
30,074
+1,626
+6% +$158K 0.64% 40
2015
Q4
$2.78M Buy
28,448
+141
+0.5% +$13.8K 0.58% 48
2015
Q3
$2.73M Buy
28,307
+373
+1% +$39.2K 0.63% 45
2015
Q2
$2.93M Buy
27,934
+1,000
+4% +$102K 0.62% 43
2015
Q1
$2.78M Sell
26,934
-200
-0.7% -$20.2K 0.59% 46
2014
Q4
$2.61M Sell
27,134
-201
-0.7% -$17.7K 0.56% 48
2014
Q3
$2.18M Sell
27,335
-2,799
-9% -$221K 0.47% 61
2014
Q2
$2.27M Sell
30,134
-497
-2% -$37.6K 0.49% 56
2014
Q1
$2.29M Buy
30,631
+600
+2% +$42.4K 0.56% 50
2013
Q4
$2.15M Sell
30,031
-748
-2% -$48.1K 0.56% 54
2013
Q3
$1.75M Sell
30,779
-1,153
-4% -$68.7K 0.49% 57
2013
Q2
$1.83M Buy
+31,932
New +$1.85M 0.54% 48

Other funds holding CVS

ProVise Management Group's CVS Position: Q1 2026 in Review

ProVise Management Group increased its CVS Health (CVS) stake by 0.06% in Q1 2026, buying an estimated $539 and bringing the position to 12,661 shares worth $909K. The position accounts for 0.07% of the portfolio, ranked #143.

ProVise Management Group first reported a position in CVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $15M in Q4 2021. 1,868 funds tracked by Wall St. Rank hold CVS as of Q1 2026.

  • ProVise Management Group held 12,661 shares of CVS Health worth $909K as of Q1 2026.
  • ProVise Management Group bought 7 CVS Health shares in Q1 2026, an estimated $539.
  • CVS Health made up 0.07% of ProVise Management Group's portfolio in Q1 2026, its #143 holding.
  • ProVise Management Group first reported a position in CVS Health in Q2 2013 and has held it in 52 quarters since.
  • ProVise Management Group's CVS Health position peaked at $15M in Q4 2021.
  • 1,868 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.

Based on ProVise Management Group's 13F filing for Q1 2026, filed 7 May 2026.